A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combinati

Trial Details

NCT ID
NCT05020236
Phase
PHASE3
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Elranatamab
  • Daratumumab
  • Pomalidomide
  • Dexamethasone
Locations (sample)
  • Clovis, California, United States|36.82523,-119.70292
  • Fresno, California, United States|36.74773,-119.77237
  • Fort Collins, Colorado, United States|40.58526,-105.08442
  • Greeley, Colorado, United States|40.42331,-104.70913
  • Aventura, Florida, United States|25.95648,-80.13921

Key Eligibility Criteria

  • Prior diagnosis of multiple myeloma as defined by IMWG criteria (Rajkumar et al, 2014).
  • Measurable disease based on IMWG criteria as defined by at least 1 of the following:
  • Serum M-protein ≥0.5 g/dL.
  • Urinary M-protein excretion ≥200 mg/24 hours.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →